Abstract
Background: Statin treatment exhibits a beneficial effect on non-alcoholic fatty liver disease (NAFLD) and on cardiovascular disease (CVD) in patients with NAFLD.
Objective: The aim of this review is to summarize the role of proprotein convertase subtilisin kexin type- 9(PCSK9) in the pathogenesis of NAFLD and discuss the effects of the new hypolipidaemic drugs PCSK9 inhibitors on NAFLD.
Results: Data indicates that high intrahepatic or circulating PCSK9 levels increase muscle and liver lipid storage, adipose energy storage and hepatic fatty acids, as well as triglycerides storage and secretion, thus contributing to the pathogenesis of NAFLD. The findings of animal and human studies, aiming to reduce PCSK9 with inhibitors (human IGG antibodies, antisense particles against PCSK9 mRNA, and small anti PCSK9 antibodies) point towards liver protection from NAFLD through inhibition of PCSK9 expression in the induction of degradation of hepatic HNF1a protein, insulin resistance (IR), and other mechanisms.
Conclusions: The use of PCSK9 inhibitors ameliorates NAFLD, aside from beneficial effects on CVD and independently of low density lipoprotein cholesterol level reduction.
Keywords: PCSK9 inhibitors, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, familial hypercholesterolemia, statin, cardiovascular disease.
Current Pharmaceutical Design
Title:The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors
Volume: 24 Issue: 31
Author(s): Eleni Theocharidou*, Marianna Papademetriou, Andromachi Reklou, Alexandros Sachinidis, Chrisoula Boutari and Olga Giouleme
Affiliation:
- Institute of Liver Studies, King's College Hospital, Denmark Hill, SE5 9RS,United Kingdom
Keywords: PCSK9 inhibitors, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, familial hypercholesterolemia, statin, cardiovascular disease.
Abstract: Background: Statin treatment exhibits a beneficial effect on non-alcoholic fatty liver disease (NAFLD) and on cardiovascular disease (CVD) in patients with NAFLD.
Objective: The aim of this review is to summarize the role of proprotein convertase subtilisin kexin type- 9(PCSK9) in the pathogenesis of NAFLD and discuss the effects of the new hypolipidaemic drugs PCSK9 inhibitors on NAFLD.
Results: Data indicates that high intrahepatic or circulating PCSK9 levels increase muscle and liver lipid storage, adipose energy storage and hepatic fatty acids, as well as triglycerides storage and secretion, thus contributing to the pathogenesis of NAFLD. The findings of animal and human studies, aiming to reduce PCSK9 with inhibitors (human IGG antibodies, antisense particles against PCSK9 mRNA, and small anti PCSK9 antibodies) point towards liver protection from NAFLD through inhibition of PCSK9 expression in the induction of degradation of hepatic HNF1a protein, insulin resistance (IR), and other mechanisms.
Conclusions: The use of PCSK9 inhibitors ameliorates NAFLD, aside from beneficial effects on CVD and independently of low density lipoprotein cholesterol level reduction.
Export Options
About this article
Cite this article as:
Theocharidou Eleni *, Papademetriou Marianna , Reklou Andromachi , Sachinidis Alexandros, Boutari Chrisoula and Giouleme Olga , The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors, Current Pharmaceutical Design 2018; 24 (31) . https://dx.doi.org/10.2174/1381612824666181010123127
DOI https://dx.doi.org/10.2174/1381612824666181010123127 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Olive Oil and Haemostasis: Platelet Function, Thrombogenesis and Fibrinolysis
Current Pharmaceutical Design Phosphodiesterase 3 (PDE3): Structure, Localization and Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Before and After Preeclampsia: What Biomarkers are there?
Current Women`s Health Reviews Intelligent Drug Delivery Systems: Polymeric Micelles and Hydrogels
Mini-Reviews in Medicinal Chemistry Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Fungal Proteins with Antiproliferative and Anticancer Activities
Protein & Peptide Letters Biological Activities of Salvia santolinifolia Boiss. A Multifunctional Medicinal Plant
Current Bioactive Compounds Targeted Therapies for Advanced Non-Small Cell Lung Cancer
Combinatorial Chemistry & High Throughput Screening The Use of Biomarkers for Assessing HAART-Associated Renal Toxicity in HIV-Infected Patients
Current HIV Research Current Technological Development of Antibody Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Modulators of the Vascular Endothelin Receptor in Blood Pressure Regulation and Hypertension
Current Molecular Pharmacology The Effects of Placental Corticotrophin Releasing Hormone on the Physiology and Psychology of the Pregnant Woman
Current Women`s Health Reviews Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Current Vascular Pharmacology Dietary Carotenoids in Managing Metabolic Syndrome and Role of PPARs in the Process
Current Nutrition & Food Science A Comparison of Biomarkers in the Assessment of Glycemic Control in Diabetes: Reviewing the Evidence
Current Diabetes Reviews Technological Options for the Production of Health-Promoting Proteins and Peptides Derived from Milk and Colostrum
Current Pharmaceutical Design Atypical Chest Pain in ACS: A Trap Especially for Women
Current Pharmaceutical Design Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy
Current Neuropharmacology Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma
Current Signal Transduction Therapy Recent Advances in Methods of Puerarin Biotransformation
Mini-Reviews in Medicinal Chemistry